The SUSTAIN-6 trial (semaglutide) and SURPASS-4 trial (tirzepatide) both demonstrated cardiovascular benefit in type 2 diabetes populations, suggesting that when appropriately prescribed, GLP-1 medications carry favorable risk-benefit profiles for metabolic health
However, genetic predisposition does not predict exact medication response or override the practical requirement for proper refrigeration
If you have a fat malabsorption disorder or follow a low fat diet, you may be at an increased risk of vitamin E deficiency
Coverage Methods Of those covering GLP-1 drugs: 86% offer the prescription drug within their medical plan 27% offer the drug through a health care spending account (HCSA) 14% offer the drug through a supplemental rider
The transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells (NF-B) has been shown to induce energy expenditure and reduce adipose tissue growth, leading to prevention of dietary obesity and lowering adipogenesis, inflammation, and IR [47]
And pancreatitis is a rare but serious side effect of Trulicity